Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings

Roche Holdings AG's RHHBY mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60% complete response rate.

• The data comes from nearly 100 patients with third-line-or-later follicular lymphoma in Phase 1/2 study dubbed GO29781.
• Pivotal results demonstrated that mosunetuzumab induces durable complete responses lasting at least 18 months in patients who have received two or more prior therapies, with a median progression-free survival of 17.9 months.
•  The median duration of response was 22.8 months among responders.
• The most common adverse event (AE) was cytokine release syndrome (CRS), generally low grade.
• Roche said it has recently submitted the initial marketing application for mosunetuzumab to the European Medicines Agency. 
• Subsidiary Genentech plans to submit the new data to the FDA soon for approval consideration. 
• If approved, mosunetuzumab can be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in NHL.
• Price Action: RHHBY shares closed at $51.12 on Friday.
• Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.